-
Tryptamine Therapeutics Advances Psilocin-Based IV Infusion To Phase 2 Clinical Trials
Tuesday, November 19, 2024 - 2:05pm | 395Read More...Tryptamine Therapeutics Ltd (OTC:TYPTF) has announced that its lead asset, TRP-8803, a psilocin-based IV infusion, will progress to Phase 2 clinical trials following a successful Phase 1b study. TRP-8803 demonstrated significant advantages over oral psilocybin, including rapid onset, precise...
-
Psychedelics And Treatment-Resistant Depression: Companies Weigh In On The Important Issue
Wednesday, November 23, 2022 - 10:05am | 1792Read More...(Part three of a four-part series) Have a look at previous stories: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes Psychedelics And Treatment-Resistant Depression: Reactions On Published Results atai Life Sciences (NASDAQ: ATAI) and COMPASS...
-
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
Thursday, November 17, 2022 - 3:48pm | 373Read More...Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science Corp. (OTC: NMLSF) for a first-of-its-kind Phase 2 clinical trial on psilocybin microdoses...
-
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
Tuesday, September 21, 2021 - 11:02am | 221Read More...Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR-255 in combination with avelumab in bladder cancer study. The Phase 2...
-
Cellectar Receives $2M NIH Grant For Rare Lymphoma Study
Wednesday, August 18, 2021 - 11:54am | 235Read More...Cellectar Biosciences Inc (NASDAQ: CLRB) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the National Cancer Institute (NCI). The Company is currently conducting a pivotal...
-
Celcuity Teams Up With MD Anderson, Novartis, Puma Biotech To Study New Drug Regimen In Breast Cancer
Wednesday, March 17, 2021 - 9:28am | 287Read More...Celcuity Inc (NASDAQ: CELC) has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NYSE: NVS), and Puma Biotechnology Inc (NASDAQ: PUMA) to conduct a Phase 2 clinical trial. The open-label Phase 2 trial will...
-
Annovis Bio Stock Is Trading Higher After Parkinson's Med Shows Improvement In Speed, Coordination
Tuesday, March 16, 2021 - 9:24am | 327Read More...Annovis Bio Inc (NYSE: ANVS) reported positive interim data from Phase 2a trial evaluating ANVS401, its lead drug candidate for Alzheimer's disease (AD) and Parkinson's disease (PD). In one test that measures the speed of execution, the results were statistically...
-
Adamis Pharma's Tempol Decreases COVID-19 Related Lung Inflammation In Animal Studies
Monday, March 15, 2021 - 10:05am | 181Read More...Adamis Pharmaceuticals Corp (NASDAQ: ADMP) has reported positive data from lab studies conducted in animal models. The study showed that Tempol-treated hamsters challenged with COVID-19 infection achieved decreased inflammation in the lungs compared to controls. The group plans...
-
Clene's Lead Candidate Shows Improvement In Functional Scores In Multiple Sclerosis Studies
Thursday, February 25, 2021 - 12:38pm | 310Read More...Clene Inc (NASDAQ: CLNN) has reported updated blinded interim data from the VISIONARY-MS Phase 2 study evaluating the efficacy and safety of lead drug candidate, CNM-Au8, in multiple sclerosis. The analyses compare changes in functional composite scores over the study...
-
Ayala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue Tumors
Friday, February 19, 2021 - 11:50am | 309Read More...Ayala Pharmaceuticals Inc (NASDAQ: AYLA) will raise $25 million via a private placement of around 1.7 million units at $15 per unit from institutional investors, including Redmile Group and SIO Capital Management. Each unit consists of one Ayala share and a warrant to purchase...
-
Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study
Tuesday, February 2, 2021 - 6:11am | 232Read More...Verona Pharma PLC (NASDAQ: VRNA) has reported positive data from the Phase 2 study evaluating pressurized metered-dose inhaler formulation (pMDI) of ensifentrine in moderate to severe chronic obstructive pulmonary disease. The study met all primary and secondary endpoints...
-
Synthetic Biologics Surges 25% Amid Positive Phase 2 Data
Wednesday, January 20, 2016 - 9:22am | 252Read More...Shares of Synthetic Biologics Inc (NYSE: SYN), a clinical-stage biotechnology company, surged higher by 25 percent at $1.90 early Wednesday morning after the company reported positive topline data from a second Phase 2 clinical trial. Synthetic Biologics stated that its second Phase 2 clinical...
